Skip to content ↓

Topic

Jameel Clinic

Download RSS feed: News Articles / In the Media / Audio

Displaying 1 - 15 of 34 news clips related to this topic.
Show:

Forbes

Prof. David Autor has been named a Senior Fellow in the Schmidt Sciences AI2050 Fellows program, and Profs. Sara Beery, Gabriele Farina, Marzyeh Ghassemi, and Yoon Kim have been named Early Career AI2050 Fellows, reports Michael T. Nietzel for Forbes. The AI2050 fellowships provide funding and resources, while challenging “researchers to imagine the year 2050, where AI has been extremely beneficial and to conduct research that helps society realize its most beneficial impacts,” explains Nietzel. 

WHDH 7

Prof. Regina Barzilay has received the WebMD Health Heros award for her work developing a new system that uses AI to detect breast cancer up to 5 years earlier, reports WHDH. “We do have a right to know our risk and then we, together with our healthcare providers, need to manage them,” says Barzilay. 

The New Yorker

New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”

BBC News

Prof. Regina Barzilay joins  BBC host Caroline Steel and other AI experts to discuss her inspiration for applying AI technologies to help improve medicine and fight cancer. “I think that in cancer and in many other diseases, the big question is always, how do you deal with uncertainty? It's all the matter of predictions," says Barzilay. "Unfortunately, today, we rely on humans who don't have this capacity to make predictions. As a result, many times people get wrong treatments or they are diagnosed much later.” 

The Economist

Prof. Regina Barzilay joins The Economist’s “Babbage” podcast to discuss how artificial intelligence could enable health care providers to understand and treat diseases in new ways. Host Alok Jha notes that Barzilay is determined to “overcome those challenges that are standing in the way of getting AI models to become useful in health care.” Barzilay explains: “I think we really need to change our mindset and think how we can solve the many problems for which human experts were unable to find a way forward.”  

Forbes

Forbes selects innovators for the list’s Healthcare & Science category, written by senior contributor Yue Wang. On the list is MIT PhD candidate Yuzhe Yang, who studies AI and machine learning technologies capability to monitor and diagnose illnesses such as Parkinson's disease.

ShareAmerica

ShareAmerica reporter Lauren Monsen spotlights Prof. Dina Katabi for her work in advancing medicine with artificial intelligence. “Katabi develops AI tools to monitor patients’ breathing patterns, hear rate, sleep quality, and movements,” writes Monsen. “This data informs treatment for patients with diseases such as Parkinson’s, Alzheimer’s, Crohn’s, and ALS (amyotrophic lateral sclerosis), as well as Rett syndrome, a rare neurological disorder.”

Fierce Biotech

In a new paper, MIT researchers detail how they have used AI techniques to discover a class of “of antibiotics capable of killing methicillin-resistant Staphylococcus aureus (MRSA),” reports Helen Floresh for Fierce Biotech. “This paper announces the first AI-driven discovery of a new class of small molecule antibiotics capable of addressing antibiotic resistance, and one of the few to have been discovered overall in the past 60 years,” says postdoctoral fellow Felix Wong.

New Scientist

Researchers at MIT have used artificial intelligence to uncover, “a new class of antibiotics that can treat infections caused by drug-resistant bacteria,” reports Jeremy Hsu for New Scientist. “Our [AI] models tell us not only which compounds have selective antibiotic activity, but also why, in terms of their chemical structure,” says postdoctoral fellow Felix Wong.

Financial Times

Researchers at MIT and elsewhere have used artificial intelligence to develop a new antibiotic to combat Acinetobacter baumannii, a challenging bacteria known to become resistant to antibiotics, reports Hannah Kuchler for the Financial Times. “It took just an hour and a half — a long lunch — for the AI to serve up a potential new antibiotic, an offering to a world contending with the rise of so-called superbugs: bacteria, viruses, fungi and parasites that have mutated and no longer respond to the drugs we have available,” writes Kuchler.

ABC News

Researchers from MIT and Massachusetts General Hospital have developed “Sybil,” an AI tool that can detect the risk of a patient developing lung cancer within six years, reports Mary Kekatos for ABC News. “Sybil was trained on low-dose chest computer tomography scans, which is recommended for those between ages 50 and 80 who either have a significant history of smoking or currently smoke,” explains Kekatos.

WCVB

Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.

Yahoo! News

Prof. Marzyeh Ghassemi speaks with Yahoo News reporter Rebecca Corey about the benefits and risks posed by the use of AI tools in health care. “I think the problem is when you try to naively replace humans with AI in health care settings, you get really poor results,” says Ghassemi. “You should be looking at it as an augmentation tool, not as a replacement tool.”

USA Today

Researchers from MIT and McMaster University have used artificial intelligence to identify a new antibiotic that can fight against a drug-resistant bacteria commonly found in hospitals and medical offices, reports Ken Alltucker for USA Today. The researchers believe the AI “process used to winnow thousands of potential drugs to identify one that may work is an approach that can work in drug discovery,” writes Alltucker.